SciSparc Ltd. SPRC 深 沪
等待开盘 05-20 09:30:00 美东时间
4.55
+0.170
+3.88%
华盛通- 最 高4.675
- 今 开4.41
- 成交量 2794股
- 最 低 4.40
- 昨 收 4.38
- 总市值 260.83万
- 52周最高 80.10
- 市盈率 静 --
- 换手率 0.49%
- 52周最低 2.98
- 委 比 74.76%
- 总股本 57.32万
- 历史最高 34791.12
- 量 比 0.10
- 振 幅 6.28%
- 历史最低 4.1589
- 每 手 1
- 风险率 21.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SciSparc Regains Conditional Nasdaq Compliance After Equity Shortfall
SciSparc Ltd. ( ($SPRC) ) just unveiled an update. On January 12, 2026, SciSpar...
05-11 20:29
Why Amazon Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with Anthropic to spend $100B on AWS.
04-21 16:43
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares moved upwards by 70.7% to $0.38 during ...
03-13 05:05
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Clearmind Medicine Inc. has published an international patent application for a novel combination therapy using MEAI and Palmitoylethanolamide (PEA) to treat obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The therapy targets a growing market valued at $37 billion in 2025 and expected to reach $226 billion by 2035. MEAI-PEA may offer a safer, non-hallucinogenic alternative to GLP-1 agonists, addressing global health ...
03-10 12:59
SciSparc Announces 1-for-9 Reverse Share Split
SciSparc Ltd. announced a 1-for-9 reverse share split effective March 4, 2026, reducing outstanding shares to approximately 565,000. No fractional shares will be issued; adjustments will be made to exercise prices and shares under options/warrants. SciSparc, through NeuroThera Labs, focuses on cannabinoid-based pharmaceuticals for treatments like Tourette's syndrome and Alzheimer's. The press release includes forward-looking statements subject to...
03-02 13:00
SciSparc Amends $10 Million Note Deal, Issues $2 Million Initial Convertible Note
SciSparc Ltd. ( ($SPRC) ) has shared an announcement. On February 12, 2026, Sci...
02-18 05:29
SciSparc Shareholders Approve February Governance Agenda
SciSparc Ltd. ( ($SPRC) ) has shared an update. Shareholders approved all propo...
02-05 05:30
CORRECTION: SciSparc Acquires MUSE IP Portfolio From Xylo in Equity-Based Asset Deal; SciSparc Issued To Xylo An Amount Of Ordinary Shares Of The Company, Which Represents 19.99% Of The Issued And Outstanding Share Capital Of SciSparc
SciSparc intends to target the global multi- billion dollar GERD device marketTEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage
01-26 21:19
SciSparc Acquires IP Portfolio Of Patents, Trademarks, IP Rights For Endoscopic Systems, Medical Cameras; Financial Terms Not Disclosed
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the closing of the
01-26 21:17
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
<p>SciSparc announced the acquisition of intellectual property from Xylo Technologies, including the MUSE™ system, designed for treating GERD. Targeting the global GERD device market valued at $2.5 billion in 2024, SciSparc plans to replicate Xylo's successful licensing model in high-growth regions to accelerate commercialization and revenue.</p>
01-26 13:13
